Brain · 2012 · 117 citations · 37 references
Life SciencesNeurologyNeuroscienceMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationAxonal DegenerationDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeurodegeneration MechanismsNeurodegenerative DiseasesDemyelination PathophysiologyDemyelination-associated Axonal LossExperimental Autoimmune EncephalomyelitisMicrotubule-associated Protein 1Multiple Sclerosis ModelsMultiple Sclerosis NeuroprotectionMultiple Sclerosis PathologyMyelin-associated Glycoprotein
Multiple sclerosis involves demyelination and axonal degeneration of the central nervous system. The molecular mechanisms of axonal degeneration are relatively unexplored in both multiple sclerosis and its mouse model, experimental autoimmune encephalomyelitis. We previously reported that targeting the axonal growth inhibitor, Nogo-A, may protect against neurodegeneration in experimental autoimmune encephalomyelitis; however, the mechanism by which this occurs is unclear. We now show that the collapsin response mediator protein 2 (CRMP-2), an important tubulin-associated protein that regulates axonal growth, is phosphorylated and hence inhibited during the progression of experimental autoimmune encephalomyelitis in degenerating axons. The phosphorylated form of CRMP-2 (pThr555CRMP-2) is localized to spinal cord neurons and axons in chronic-active multiple sclerosis lesions. Specifically, pThr555CRMP-2 is implicated to be Nogo-66 receptor 1 (NgR1)-dependent, since myelin oligodendrocyte glycoprotein (MOG)(35-55)-induced NgR1 knock-out (ngr1(-)(/)(-)) mice display a reduced experimental autoimmune encephalomyelitis disease progression, without a deregulation of ngr1(-)(/)(-) MOG(35-55)-reactive lymphocytes and monocytes. The limitation of axonal degeneration/loss in experimental autoimmune encephalomyelitis-induced ngr1(-)(/)(-) mice is associated with lower levels of pThr555CRMP-2 in the spinal cord and optic nerve during experimental autoimmune encephalomyelitis. Furthermore, transduction of retinal ganglion cells with an adeno-associated viral vector encoding a site-specific mutant T555ACRMP-2 construct, limits optic nerve axonal degeneration occurring at peak stage of experimental autoimmune encephalomyelitis. Therapeutic administration of the anti-Nogo(623-640) antibody during the course of experimental autoimmune encephalomyelitis, associated with an improved clinical outcome, is demonstrated to abrogate the protein levels of pThr555CRMP-2 in the spinal cord and improve pathological outcome. We conclude that phosphorylation of CRMP-2 may be downstream of NgR1 activation and play a role in axonal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Blockade of Nogo-A/NgR1 interaction may serve as a viable therapeutic target in multiple sclerosis.
37
Axonal Transection in the Lesions of Multiple Sclerosis
Bruce D. Trapp, John W. Peterson, Richard M. Ransohoff et al. · New England Journal of Medicine · 1998 · 4K citations · Full text
Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein
Tadzia GrandPré, Fumio Nakamura, Timothy Vartanian et al. · Nature · 2000 · 1.1K citations